Novo Nordisk's Wegovy Pill Gets US FDA Approval for Weight Reduction

11:15 PM EST, 12/22/2025 (MT Newswires) -- Novo Nordisk's (NOVO-B.CO) weight loss pill Wegovy secured the US Food and Drug Administration's approval as the first oral glucagon-like peptide-1 to reduce body weight and risk of adverse cardiovascular events. The approval is backed by the Oasis 4 and Select trials, which showed that the pill demonstrated a mean weight loss of 16.6% in adults who took the pill once daily and were obese or overweight with one or more comorbidities, according to a Monday release. Furthermore, the Oasis 4 showed that the pill led to a 20% or greater reduction in weight in one in three people in the trial. The Danish drugmaker anticipates the launch of the pill in the US at the start of January 2026.